Great debate Re TNT approach young pt ugly disease: US/Canada/Aus differing use DPYD, irinotecan, consolidation v induction, W+W: MDT discussion and consideration pt goals paramount #AGITG23 GI Cancer Institute and AGITG

What do we need to know about an individual to care for & work with them effectively? #AGITG23

The prognosis for brain tumours has always been difficult to define. Today, Hao-Wen Sim & Ned McNamee present research at SNO on how comprehensive genomic profiling can assist in this astrocytoma prognostication. Subo Garvan Institute of Medical Research St Vincent's Sydney #OncTwitter

seek.com.au/job/71555508 Job opportunity! looking for an oncology haematology career medical officer to join SVPH - inpatient and outpatient (ambulantory care) duties - balanced workload and no on call - enquire within! St Vincent's Sydney ONCODOC Dion Forstner

Thrilled to lead this exciting project deciphering young-onset colorectal cancer alongside Megan Barnet @KylieReneeJames and Dr Subo Thavaneswaran 🥳

Great summary from Ryan Corcoran Mass General Cancer Center re targeting RAS. Similar single agent ORR G12Cinh PDAC compared w/ NSCLC, vs CRC which improves w/ addition anti-EGFR. Supports KRAS good target in PDAC …just need to progress in G12D #ESMOGI24

Further consideration of ESOPEC w Ian Chau - FLOT in Germany > FLOT rest-of-world? pCR FLOT4, DANTE, ESOPEC 15-17% vs others ~7% #ESMOGI24

Masterclass in ctDNA from Jeanne Tie at #ESMOGI24. Efforts to improve sensitivity inc: track more muts (WES vs panel), reduce BG noise (seq PBMCs, technical improvements), increase cf DNA input (how much blood ethically ok w serial collections) #aussiesonthepodium

A reminder from Prof Karin Haustermans of why rad oncs dislike PROSPECT (…aside from inclusion of patients who didn’t need NA tx) #ESMOGI24

RV of rationale for differing OS + ongoing pref up-front surgery Asian v Western gastric w/ Prof Sun Young Rha Yonsei University: 5yOS >60 v 25% ! Screening program/more early disease, long-standing D2 dissection SoC, diff histo path (non-cardia > cardia). #ESMOGI24

Unsurprising QoL data for TRANSMET, late deviation in favour LT+C v C. Interesting summary from Chiara Cremolini re pattern of relapse liver TP (lung dominant) v resection (liver dominant) #ESMOGI24

KN585 OS (noting EFS/trial stat. neg despite 20m improvement) OS benefit 6% at5yrs. FLOT (v CF) backbone did better (cis poor PD1 partner), but only 20% cohort, clear benefit CPS >10/MSI-H. Appealing option; may solidify w MATTERHORN survival (100% FLOT) Kohei shitara #ESMOGI24

Thought provoking talk from Prof. Irit Ben-Aharon on QoL issues in EOCRC, esp paucity of data re: fertility pres. w/ RT + oxali (can’t extrapolate GnRHa from CTX - can worsen problem), cardiovascular tox (CVD 54% CRC survivors v 17% Gen pop), psychosocial, body image, sexual fnc #ESMOGI24

Laurence Zitvogel Gustave Roussy tour de force microbiome. Meta-anal. AB use -60 to +42d C1 PD1; surge pathogenic bact. post AB down-reg gut checkpoint MadCAM —> exodus immunosupp cells inc Th17 from gut to cancer. PD1 at this point amplifies exodus 🪨/doc/hard place #ESMOGI24

PDAC has more negative trials than any other tumour stream… Trying to find Prof Thomas Seufferlein’s summary slide motivating rather than deflating. Nal-iri combos underwhelming and not compared to FOLFIRI/mFFX #ESMOGI24

Biological rationale of EGFR-MET Bispec Ab Amivantamab w/ Josep Tabernero; averting met-amplification rel. resistance, inducing ADCC. We will test in 1L Ph3 ORIGAMI-2 trial w/ platinum doublet vs CT/cetux in RAS/BRAFwt L-sided mCRC opening soon👊 The Kinghorn Cancer Centre #ESMOGI24

Summary ongoing BRAFm mCRC trials w/ Dominik Paul Modest 1L BREAKWATER MSS Ph3 enco/cetux +/CT v CT-bev 1L SEAMARK MSI Ph2 enco/cetux/pembro v pembro 2L SWOG2107 MSS Ph2 enco/cetux v enco/cetux/nivo 3L BRICKET (🦗) Ph2 rechallenge enco/cetux if no alt ctDNA #ESMOGI24

Promising ORR 32% in CLDN18.2 mod/high (90% cohort) heavily pre treated pt w/ G/GOJ. Similar responses, less N/V than other CLDN18.2 Abs Jia (Jenny) Liu The Kinghorn Cancer Centre #ESMOGI24

TOPAZ-1 update at mFU 41m - OS HR strengthened 0.8 —> 0.74, if have a CR/PR 1/3 alive at 3y vs 16% chemo. 17% ‘long term’ survivors, across all subgroups iCCA/eCCA/GBC/ROW/PDL1 #ESMOGI24

Heading home to my very own #messehaus. Thanks #ESMOGI24 Teresa Macarulla Ducreux Michel and Prof Eric Van Cutsem for a fantastic program and amazing week in Munich! Jia (Jenny) Liu The Kinghorn Cancer Centre